When a loved one starts immunotherapy for melanoma, the treatment schedule and clinic appointments become very important to family life. Checkpoint inhibitors – drugs such as pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) – are now a core part of melanoma treatment. They can produce lasting responses in many patients, but they also cause side effects that differ from chemotherapy. As a caregiver, understanding these side effects helps you act at the right time.
How Checkpoint Inhibitors Work – and Why They Cause Side Effects
Checkpoint inhibitors remove molecular brakes that normally stop the immune system from attacking healthy tissue. That is what makes them useful against cancer. But when those brakes come off, the immune system can also target normal organs. The resulting problems are called immune-related adverse events, or irAEs. They can affect almost any body system: skin, bowel, lungs, liver, joints, thyroid gland, or the pituitary and adrenal glands.
According to the American Cancer Society, common side effects of checkpoint inhibitors include fatigue, skin rash, diarrhea, nausea, joint pain, and changes in appetite. Less common but serious irAEs include inflammation of the lungs (pneumonitis), liver (hepatitis), and colon (colitis). Endocrine gland problems – particularly thyroid and pituitary – are also well documented.
A review of immune-mediated adverse events in melanoma found that for patients receiving anti-PD-1 therapy, hypothyroidism, rash, pruritus, and arthralgia were among the most commonly reported irAEs, while pneumonitis and colitis occurred less frequently but required prompt management. The full review is available at PMC (immune-mediated adverse events in melanoma). Most irAEs appear in the first weeks to months of treatment. Some occur after treatment has ended. This means caregivers should watch for symptoms throughout treatment, not just at the start.
Recognizing and Managing Fatigue
Fatigue is the most frequently reported side effect during immunotherapy. The National Cancer Institute Fatigue PDQ describes cancer-related fatigue as a persistent sense of exhaustion that is not proportional to recent activity and does not improve fully with rest. This is different from ordinary tiredness.
For caregivers, here is the key difference: normal tiredness gets better after a night of sleep. Cancer-related fatigue often does not. Your loved one may feel exhausted after doing very little. They may need rest after a short walk or a brief conversation. This is not weakness. It is a documented biological response to treatment.
Several underlying causes can drive fatigue during immunotherapy:
- Thyroid dysfunction. Immune-related hypothyroidism is one of the more common endocrine irAEs. An underactive thyroid slows the body’s metabolism and often produces profound fatigue, weight gain, and low mood. The NCI notes that endocrine disorders such as hypothyroidism and adrenal insufficiency should be excluded when fatigue is present during treatment.
- Adrenal insufficiency. The immune system can damage the adrenal glands, reducing cortisol production. This causes extreme fatigue, low blood pressure, nausea, and dizziness. It requires prompt medical assessment.
- Anemia. Some patients develop immune-related destruction of red blood cells, which compounds exhaustion and can cause shortness of breath.
- Poor sleep. Pain, anxiety, and disrupted routines interfere with sleep quality, which makes daytime fatigue significantly worse.
Practical steps caregivers can take include keeping a brief daily log of fatigue levels using a simple 0-to-10 scale. This gives the oncology team a pattern to work with at each visit. Help plan the day so that important tasks – bathing, eating, short walks – happen during your loved one’s best-energy window, which is often mid-morning for many patients. Protect afternoon rest periods and avoid scheduling demanding activities in the late afternoon.
If fatigue appears to be worsening between appointments, or if it comes alongside unusual cold sensitivity, weight gain, or dizziness on standing, contact the team before the next scheduled visit. These can signal a thyroid or adrenal problem that needs a blood test right away.
Mood Changes: What Is Normal and What Needs Medical Attention
Mood changes during melanoma immunotherapy come from two sources. The first is the psychological weight of a cancer diagnosis and treatment. The second is a direct biological effect of immunotherapy on the brain and hormones.
Anxiety and depression are the most frequently reported psychiatric conditions linked to cancer-related fatigue, according to the American Cancer Society’s fatigue resource. Mood problems can worsen fatigue, and fatigue can worsen mood.
From a biological standpoint, endocrine irAEs can produce mood symptoms that look like standard depression or anxiety but are actually caused by thyroid or pituitary gland damage. Hypothyroidism and hypopituitarism both alter hormone levels in ways that affect mood, concentration, and energy. This is why a new or worsening mood change during immunotherapy deserves a medical evaluation, not just reassurance.
Signs that a mood change may need same-week medical attention:
- Sudden onset of confusion or unusual forgetfulness – these can indicate pituitary inflammation (hypophysitis) or low sodium caused by adrenal problems
- Mood change alongside new physical symptoms such as a persistent headache, unusual thirst, or unexplained weight change
- Any statement about self-harm or hopelessness – contact the oncology team or a crisis support line right away
Signs that are still worth reporting but are not immediate emergencies:
- Persistent low mood lasting more than two weeks
- Increased irritability or emotional sensitivity not explained by recent events
- Withdrawal from activities or people your loved one normally enjoys
- Difficulty concentrating on simple daily tasks
Many cancer centers offer psychology or social work services as part of the oncology team. Ask for a referral early. There is no need to wait until mood problems become severe before seeking that support.
When to Contact Your Oncology Team
Part of your role as a caregiver is to notice changes that your loved one might minimize or not mention. Patients sometimes underreport symptoms because they fear that reporting will lead to stopping a treatment that is working. Reassure them that the oncology team needs accurate information to manage irAEs safely – and that many side effects can be treated without stopping therapy if they are caught early.
Call the oncology team’s after-hours line within 24 hours if you observe any of the following:
- New or significantly worsened diarrhea (more than 4 loose stools per day above what is normal for your loved one)
- Skin blistering or a spreading widespread rash, not just mild redness
- New cough, shortness of breath, or chest tightness not explained by a known condition
- Yellowing of the skin or the whites of the eyes
- Severe fatigue with dizziness or light-headedness on standing
- New muscle weakness, double vision, or difficulty swallowing
- Significant joint swelling, not just mild morning stiffness
- A new severe headache, particularly with vision changes or light sensitivity
When to Go to the Emergency Room
Some irAEs are medical emergencies that cannot wait for a clinic callback. Go directly to the emergency room – or call emergency services – if your loved one experiences any of the following:
- Severe difficulty breathing or an oxygen saturation reading below 92 percent on a home monitor
- Chest pain of any kind
- Sudden confusion, loss of consciousness, or a severe headache accompanied by neurological symptoms such as arm weakness or speech difficulty
- Signs of shock: pale skin, rapid weak pulse, fainting, or a very low blood pressure reading
- High fever (above 38.5 degrees C or 101.3 degrees F) with chills and a suspected infection
- Severe abdominal pain with a hard or distended abdomen
Bring a list of all current medications and the name of the immunotherapy drug to every emergency visit. Tell the emergency team that your loved one is receiving checkpoint inhibitor therapy. This matters because the standard treatment for many irAEs involves corticosteroids, and the emergency team needs this context to make safe decisions quickly.
Practical Day-to-Day Caregiving
Structure and communication are the two most useful tools a caregiver has. Consistent routines – fixed times for meals, medications, and rest – reduce decision fatigue for both of you. A shared symptom log tracking energy levels, appetite, bowel habits, sleep quality, and mood gives the oncology team a clear picture at every visit.
Prepare a short written summary before each oncology appointment. Include any new symptoms, changes since the previous visit, current medications and supplements, and any questions from you or your loved one. A written list prevents important items from being forgotten under the time pressure of a clinic visit.
Research involving melanoma and lung cancer patients receiving checkpoint inhibitors shows that caregivers play a key role in recognizing and reporting side effects, often noticing changes before the patient acknowledges them. A qualitative study published in PMC involving patients on immunotherapy and their caregivers found that learning to manage toxicity was an ongoing process – one that required clear communication with the clinical team and consistent attention to day-to-day changes at home.
Caregiver burnout is a real risk. Set reasonable limits on what you can do in a single day. Accept help from other family members or community services when it is offered. Some hospitals have caregiver support groups specifically for people supporting patients on immunotherapy. Ask the oncology social worker what is available at your treatment center.
Integrative Support: What to Discuss with Your Team
Some patients and caregivers ask about supplements or lifestyle measures that may help manage fatigue or support general wellbeing during immunotherapy. This is a reasonable topic to raise with the oncology team, but ask first before trying anything new. Some compounds interact with immune pathways in ways that could affect how treatment works.
Sleep is one area where evidence-based approaches tend to align across conventional and integrative practice. Poor sleep significantly worsens both fatigue and mood. Sleep hygiene strategies – a consistent bedtime, limiting screen use before sleep, and managing light and noise in the bedroom – are low-risk and worth starting early. For patients whose sleep disruption is more persistent, the oncology team can assess whether a specific supplement at a studied dose may be appropriate alongside other interventions. Our article on melatonin dosing for sleep and fatigue during checkpoint inhibitor treatment outlines the available evidence and dose ranges studied in clinical settings – useful background before raising the topic with the team.
Vitamin D is another nutrient that frequently comes up for melanoma patients. People with melanoma are typically advised to limit sun exposure, which reduces the skin’s ability to synthesize vitamin D. For more detail on this specific issue, see our article on melanoma survivorship and vitamin D, which covers current evidence on supplementation and bone health for this group.
For caregivers researching broader supportive care options, integrative oncology formulations list evidence-cited options that some oncology teams incorporate alongside conventional treatment. Any product should be discussed with the treating oncologist before use, particularly during active checkpoint inhibitor therapy, where interaction potential is not always obvious.
Before Starting Any New Supplement or Medication
If your loved one is receiving prescription immunotherapy, is pregnant, or is breastfeeding, please discuss any new supplement, herbal product, or over-the-counter medication with their oncology team before starting it. Interactions with checkpoint inhibitors can be clinically significant and are not always obvious.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
